Combined use of zoledronic acid and 153Sm-EDTMP in hormone-refractory prostate cancer patients with bone metastases

PURPOSE: (153)Sm-ethylenediaminetetramethylenephosphonic acid (EDTMP; Quadramet®) is indicated for the treatment of painful bone metastases, whereas zoledronic acid (Zometa®) is indicated for the prevention of skeletal complications. Because of the different therapeutic effects, combining the treatm...

Descripción completa

Detalles Bibliográficos
Autores principales: Lam, Marnix G. E. H., Dahmane, Amel, Stevens, Wil H. M., van Rijk, Peter P., de Klerk, John M. H., Zonnenberg, Bernard A.
Formato: Texto
Lenguaje:English
Publicado: Springer-Verlag 2007
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2668561/
https://www.ncbi.nlm.nih.gov/pubmed/18157530
http://dx.doi.org/10.1007/s00259-007-0659-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2668561/
https://www.ncbi.nlm.nih.gov/pubmed/18157530
http://dx.doi.org/10.1007/s00259-007-0659-z

Ejemplares similares